Ten years of anti-vascular endothelial growth factor therapy

被引：0
作者：
Napoleone Ferrara
Anthony P. Adamis
机构：
[1] University of California,
[2] San Diego,undefined
[3] Genentech,undefined
[4] Inc.,undefined
来源：
Nature Reviews Drug Discovery | 2016年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Over the past 10 years, targeting vascular endothelial growth factor A (VEGFA) has been widely pursued in the treatment of various cancers and ophthalmic diseases. Here, Ferrara and Adamis provide an overview of the discovery of VEGFA and the development of anti-VEGFA therapies, addressing key challenges and issues that remain in the application of these agents.
引用
收藏
页码：385 / 403
页数：18
相关论文
共 456 条
  • [81] Davis-Smyth T(2006)Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity N. Engl. J. Med. 355 2542-2550
  • [82] Chen H(2003)The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors N. Engl. J. Med. 349 427-434
  • [83] Park J(2008)Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies J. Clin. Oncol. 26 5422-5428
  • [84] Presta LG(2010)Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy J. Clin. Oncol. 28 2144-2150
  • [85] Ferrara N(2009)Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer J. Clin. Oncol. 27 4733-4740
  • [86] Ambati BK(2009)Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J. Clin. Oncol. 27 740-745
  • [87] Herbert SP(2014)Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 N. Engl. J. Med. 370 709-722
  • [88] Stainier DY(2014)Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised Phase 3 trial N. Engl. J. Med. 370 699-708
  • [89] Carmeliet P(2014)Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell-lung cancer N. Engl. J. Med. 370 734-743
  • [90] Ferrara N(2014)A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer J. Clin. Oncol. 32 1302-1308
45678910111213